Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $36,720.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 10,800 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $36,720.00. Following the completion of the transaction, the director now directly owns 43,550 shares in the company, valued at $148,070. This trade represents a 19.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Puma Biotechnology Stock Performance

Shares of PBYI traded down $0.21 during mid-day trading on Friday, reaching $3.19. 314,744 shares of the company's stock were exchanged, compared to its average volume of 443,070. The business's fifty day simple moving average is $3.22 and its 200-day simple moving average is $3.12. Puma Biotechnology, Inc. has a 52-week low of $2.23 and a 52-week high of $4.13. The stock has a market capitalization of $158.32 million, a PE ratio of 4.14 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43.

Institutional Investors Weigh In On Puma Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in PBYI. Wells Fargo & Company MN grew its stake in shares of Puma Biotechnology by 36.5% in the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock valued at $70,000 after purchasing an additional 6,126 shares during the last quarter. Mackenzie Financial Corp purchased a new position in Puma Biotechnology in the 4th quarter valued at $240,000. Bank of New York Mellon Corp increased its stake in Puma Biotechnology by 19.5% in the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company's stock valued at $1,012,000 after buying an additional 54,150 shares during the period. American Century Companies Inc. lifted its stake in shares of Puma Biotechnology by 8.4% in the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock worth $2,893,000 after acquiring an additional 73,833 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Puma Biotechnology by 182.3% in the fourth quarter. JPMorgan Chase & Co. now owns 136,897 shares of the biopharmaceutical company's stock valued at $418,000 after acquiring an additional 88,404 shares in the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.